Brain Tumor Res Treat.  2023 Apr;11(2):133-139. 10.14791/btrt.2023.0010.

The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Survey About Specific Clinical Scenarios (Version 2023.1)

• Kim MS
• Go SI
• Wee CW
• Lee MH
• Kang SG
• Go KO
• Kwon SM
• Kim W
• Dho YS
• Park SH
• Seo Y
• Song SW
• Ahn S
• Oh HJ
• Yoon HI
• Lee SW
• Lee JH
• Cho KR
• Choi JW
• Hong JB
• Hwang K
• Park CK
• Lim DH
• KSNO Guideline Working Group

• KMID: 2542085
• DOI: http://doi.org/10.14791/btrt.2023.0010

Abstract

Background
During the coronavirus disease 2019 (COVID-19) pandemic, there was a shortage of medical resources and the need for proper treatment guidelines for brain tumor patients became more pressing. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, has undertaken efforts to develop a guideline that is tailored to the domestic situation and that can be used in similar crisis situations in the future. As part II of the guideline, this consensus survey is to suggest management options in specific clinical scenarios during the crisis period.
Methods
The KSNO Guideline Working Group consisted of 22 multidisciplinary experts on neuro-oncology in Korea. In order to confirm a consensus reached by the experts, opinions on 5 specific clinical scenarios about the management of brain tumor patients during the crisis period were devised and asked. To build-up the consensus process, Delphi method was employed.
Results
The summary of the final consensus from each scenario are as follows. For patients with newly diagnosed astrocytoma with isocitrate dehydrogenase (IDH)-mutant and oligodendroglioma with IDH-mutant/1p19q codeleted, observation was preferred for patients with low-risk, World Health Organization (WHO) grade 2, and Karnofsky Performance Scale (KPS) ≥60, while adjuvant radiotherapy alone was preferred for patients with high-risk, WHO grade 2, and KPS ≥60. For newly diagnosed patients with glioblastoma, the most preferred adjuvant treatment strategy after surgery was radiotherapy plus temozolomide except for patients aged ≥70 years with KPS of 60 and unmethylated MGMT promoters. In patients with symptomatic brain metastasis, the preferred treatment differed according to the number of brain metastasis and performance status. For patients with newly diagnosed atypical meningioma, adjuvant radiation was deferred in patients with older age, poor performance status, complete resection, or low mitotic count.
Conclusion
It is imperative that proper medical care for brain tumor patients be sustained and provided, even during the crisis period. The findings of this consensus survey will be a useful reference in determining appropriate treatment options for brain tumor patients in the specific clinical scenarios covered by the survey during the future crisis.

Keyword

Korean Society for Neuro-Oncology; Crisis; Astrocytoma; Oligodendroglioma; Glioblastoma; Brain metastases; Meningioma; Guideline

Reference

1. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005; 366:985–990. PMID: 16168780.

2. Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016; 374:1344–1355. PMID: 27050206.

3. Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, et al. NCCN Guidelines® insights: central nervous system cancers, version 2.2022. J Natl Compr Canc Netw. 2023; 21:12–20. PMID: 36634606.

4. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013; 31:337–343. PMID: 23071247.

5. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014; 32:783–790. PMID: 24516018.

6. Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G. ESMO Guidelines Working Group. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii93–ii101. PMID: 24782454.

7. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013; 31:344–350. PMID: 23071237.

8. Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, et al. CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro Oncol. 2021; 23:457–467. PMID: 32678879.

9. Esteyrie V, Dehais C, Martin E, Carpentier C, Uro-Coste E, Figarella-Branger D, et al. Radiotherapy plus procarbazine, lomustine, and vincristine versus radiotherapy plus temozolomide for IDH-mutant anaplastic astrocytoma: a retrospective multicenter analysis of the French POLA cohort. Oncologist. 2021; 26:e838–e846. PMID: 33524191.

10. van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, et al. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2021; 22:813–823. PMID: 34000245.

11. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012; 13:707–715. PMID: 22578793.

12. Malmstrom A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13:916–926. PMID: 22877848.

13. Bernhardt D, Wick W, Weiss SE, Sahgal A, Lo SS, Suh JH, et al. Neurooncology management during the COVID-19 pandemic with a focus on WHO grade III and IV gliomas. Neuro Oncol. 2020; 22:928–935. PMID: 32369601.

14. Wee CW, Yoon HI, Lee SW, Lim DH. Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21-05). Jpn J Clin Oncol. 2022; 52:843–849. PMID: 35453150.

15. Wee CW, Kim IH, Park CK, Kim N, Suh CO, Chang JH, et al. Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort: is short-course radiotherapy enough or is it a matter of selection? J Neurooncol. 2020; 148:57–65. PMID: 32361863.

16. Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021; 32:1332–1347. PMID: 34364998.

17. Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2022; 40:492–516. PMID: 34932393.

18. Rades D, Bohlen G, Dunst J, Lohynska R, Veninga T, Stalpers L, et al. Comparison of short-course versus long-course whole-brain radiotherapy in the treatment of brain metastases. Strahlenther Onkol. 2008; 184:30–35. PMID: 18188520.

19. Graham PH, Bucci J, Browne L. Randomized comparison of whole brain radiotherapy, 20 Gy in four daily fractions versus 40 Gy in 20 twice-daily fractions, for brain metastases. Int J Radiat Oncol Biol Phys. 2010; 77:648–654. PMID: 19836153.

20. Neuro-oncology treatment guidance during COVID-19 pandemic. London: Royal College of Radiologists;updated March 27, 2020. Accessed March 3, 2023. at https://www.rcr.ac.uk/sites/default/files/neuro-oncology-treatment-covid-19.pdf.

21. Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021; 23:1821–1834. PMID: 34181733.

22. NCCN clinical practice guidelines in oncology. Central nervous system cancers. Plymouth Meeting, PA: NCCN;updated 2022. Accessed March 3, 2023. at https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.

23. Byun HK, Chang WI, Lee JH, Park CK, Kim IA, Kim CY, et al. Adjuvant radiotherapy versus surveillance for grade 2 intracranial meningiomas: a multi-institutional propensity score-matched study. Front Oncol. 2022; 12:877244. PMID: 35847889.

24. Dziuk TW, Woo S, Butler EB, Thornby J, Grossman R, Dennis WS, et al. Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol. 1998; 37:177–188. PMID: 9524097.

25. Sarhan N, Abduljabbar L, Laperriere N, Shultz D, Asha M, Zadeh G, et al. Short course hypofractionated radiotherapy for frail or elderly patients with meningioma. Cureus. 2020; 12:e8604. PMID: 32676243.